Lenalidomide is active for extramedullary disease in refractory multiple myeloma

被引：14
|
作者：
Nakazato, Tomonori [1 ]
Mihara, Ai [1 ]
Ito, Chisako [1 ]
Sanada, Yukinari [1 ]
Aisa, Yoshinobu [1 ]
机构：
[1] Yokohama Municipal Citizens Hosp, Dept Hematol, Hodogaya Ku, Yokohama, Kanagawa 2408555, Japan
来源：
ANNALS OF HEMATOLOGY | 2012年 / 91卷 / 03期
关键词：
THALIDOMIDE; BORTEZOMIB;
D O I：
10.1007/s00277-011-1272-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：473 / 474
页数：2
相关论文
共 50 条
  • [21] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    Siegel, D. S.
    Richardson, P.
    Dimopoulos, M.
    Moreau, P.
    Mitsiades, C.
    Weber, D.
    Houp, J.
    Gause, C.
    Vuocolo, S.
    Eid, J.
    Graef, T.
    Anderson, K. C.
    BLOOD CANCER JOURNAL, 2014, 4 : e182 - e182
  • [22] Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
    Palumbo, A.
    Larocca, A.
    Falco, P.
    Sanpaolo, G.
    Falcone, A. P.
    Federico, V.
    Canepa, L.
    Crugnola, M.
    Genuardi, M.
    Magarotto, V.
    Petrucci, M. T.
    Boccadoro, M.
    LEUKEMIA, 2010, 24 (05) : 1037 - 1042
  • [23] Lenalidomide A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma
    Scott, Lesley J.
    Lyseng-Williamson, Katherine A.
    DRUGS, 2011, 71 (05) : 625 - 649
  • [24] Lenalidomide in multiple myeloma
    Thomas, Sheeba K.
    Richards, Tiffany A.
    Weber, Donna M.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) : 717 - 735
  • [25] Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma
    Sachin R. Shah
    Thu M. Tran
    Drugs, 2007, 67 : 1869 - 1881
  • [26] Bortezomib:: an effective agent in extramedullary disease in multiple myeloma
    Laura, R
    Cibeira, MT
    Uriburu, C
    Yantorno, S
    Salamero, O
    Bladé, J
    Montserrat, E
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (05) : 405 - 408
  • [27] Cytogenetics in multiple myeloma patients progressing into extramedullary disease
    Besse, Lenka
    Sedlarikova, Lenka
    Greslikova, Henrieta
    Kupska, Renata
    Almasi, Martina
    Penka, Miroslav
    Jelinek, Tomas
    Pour, Ludek
    Adam, Zdenek
    Kuglik, Petr
    Krejci, Marta
    Hajek, Roman
    Sevcikova, Sabina
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (01) : 93 - 100
  • [28] Lenalidomide use in multiple myeloma (Review)
    Zhang, Chao-Wei
    Wang, Ya-Nan
    Ge, Xue-Ling
    MOLECULAR AND CLINICAL ONCOLOGY, 2024, 20 (01)
  • [29] Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
    Nijhof, Inger S.
    Franssen, Laurens E.
    Levin, Mark-David
    Bos, Gerard M. J.
    Broijl, Annemiek
    Klein, Saskia K.
    Koene, Harry R.
    Bloem, Andries C.
    Beeker, Aart
    Faber, Laura M.
    van der Spek, Ellen
    Ypma, Paula F.
    Raymakers, Reinier
    van Spronsen, Dick-Johan
    Westerweel, Peter E.
    Oostvogels, Rimke
    van Velzen, Jeroen
    van Kessel, Berris
    Mutis, Tuna
    Sonneveld, Pieter
    Zweegman, Sonja
    Lokhorst, Henk M.
    van de Donk, Niels W. C. J.
    BLOOD, 2016, 128 (19) : 2297 - 2306
  • [30] Facing lenalidomide-refractory myeloma
    Cavo, Michele
    BLOOD, 2019, 134 (02) : 99 - 101
12345